13F GuideFiling Basics
What is SEC Form 13F? Ultimate Guide to Institutional Equity Filings
Learn how SEC Form 13F filings work, the $100M threshold, 45-day reporting lag, and how to track top hedge fund holdings.
AlphaSMO Research GuideRead Guide
CIK: 0001388551
Total reported value
$1.9M
$1.9M
11 檔
510.1%
In Q2 2025, Caxton CORP's U.S. equity holdings reached a combined market value of $1.9M, distributed across 11 disclosed stock positions.
Caxton CORP executed strategic sector rebalancing during Q2 2025, establishing 1 new positions while fully exiting 2 holdings and trimming 1 positions.
In terms of portfolio concentration, the top 5 core holdings (including RZLT, GLD, BRK-B) accounted for 510.1% of total reported equity market value during Q2 2025.
| # | Ticker | Issuer | Asset Subclass | Weight | Weight Change | Shares Change | 4Q Trend |
|---|---|---|---|---|---|---|---|
| 1 | RZLT | Rezolute Inc | Stock-Other | 72.60% | — | +21.61% | |
| 2 | GLD | Spdr Gold Shares | ETF-Commodities | 15.32% | -81.50% | EXIT | |
| 3 | BRK-B | Berkshire Hathaway Inc-cl B | Stock-Other | 3.12% | +11.69% | +35.33% | |
| 4 | ELVN | Enliven Therapeutics Inc | Stock-Other | 2.67% | — | — | |
| 5 | BRD1EUR | Mind Medicine Mindmed Inc | Stock-Other | 2.24% | — | — | |
| 6 | CMPX | Compass Therapeutics Inc | Stock-Other | 1.15% | — | — | |
| 7 | BCAX | Bicara Therapeutics Inc | Stock-Other | 1.03% | — | — | |
| 8 | KYTX | Kyverna Therapeutics Inc | Stock-Other | 0.72% | +1.91% | — | |
| 9 | LXEO | Lexeo Therapeutics Inc | Stock-Other | 0.71% | +2.27% | -2.91% | |
| 10 | IKT | Inhibikase Therapeutics Inc | Stock-Other | 0.32% | +1.93% | — | |
| 11 | CNTX | Context Therapeutics Inc | Stock-Other | 0.12% | — | — |
| # | Ticker | Issuer | Weight Change | Shares Change | Action |
|---|---|---|---|---|---|
| 1 | GLD | Spdr Gold Shares | +8% | +281.51% | Add |
| 2 | ELVN | Enliven Therapeutics Inc | +2.7% | NEW | New buy |
| 3 | CNTX | Context Therapeutics Inc | -0.1% | — | Unchanged |
| 4 | KYTX | Kyverna Therapeutics Inc | -0.2% | — | Unchanged |
| 5 | TORCEUR | Adicet Bio Inc | -0.3% | EXIT | Sold out |
| 6 | IKT | Inhibikase Therapeutics Inc | -0.4% | — | Unchanged |
| 7 | CMPX | Compass Therapeutics Inc | -0.5% | — | Unchanged |
| 8 | LXEO | Lexeo Therapeutics Inc | -0.5% | -2.91% | Trim |
| 9 | CRDF | Cardiff Oncology Inc | -0.8% | EXIT | Sold out |
| 10 | BRD1EUR | Mind Medicine Mindmed Inc | -1.7% | — | Unchanged |
| 11 | BRK-B | Berkshire Hathaway Inc-cl B | -1.8% | +35.33% | Add |
| 12 | BCAX | Bicara Therapeutics Inc | -1.8% | — | Unchanged |
| 13 | RZLT | Rezolute Inc | -2.7% | +21.61% | Add |
According to official SEC Form 13F filings, Caxton CORP reported a total U.S. public equity portfolio value of $1.9M across 11 disclosed positions in Q2 2025.
During Q2 2025, Caxton CORP's top holdings by market value included RZLT (72.6%)、GLD (15.3%)、BRK-B (3.1%). The largest single position, RZLT, represented 72.6% of total portfolio value.
Expert Analysis & Guides for Tracking Wall Street Smart Money Movements
Learn how SEC Form 13F filings work, the $100M threshold, 45-day reporting lag, and how to track top hedge fund holdings.
Top New Position Initiated
ELVN
市值: $262.7K
Top Position Liquidated / Trimmed
CRDF
前期市值: $41.7K
In Q2 2025, Caxton CORP made 7 total portfolio adjustments, initiating 1 new buys, adding to 3 positions, trimming 1 holdings, and fully liquidating 2 stocks.
All holding records on this page are fetched directly from the U.S. Securities and Exchange Commission (SEC) EDGAR system (Form 13F-HR). AlphaSMO parses CUSIP identifiers and formats data into Schema.org-compliant datasets.
Understand SEC Form 4 insider disclosures for corporate officers, directors, and 10% owners to track executive transactions.
Understand Rule 144 restricted stock sale notices to spot planned insider liquidations before market sell pressure arrives.
Explore the 5% beneficial ownership threshold, 13D vs 13G filing differences, and recent SEC accelerated deadline rules.
Best practices for analyzing 13F quarterly changes without getting misled by stock splits, options, or market valuation drift.
Learn how AlphaSMO's flagship signal detects high-conviction stocks where 13F hedge funds and corporate insiders buy at the same time.